Bruce David G, Davis Wendy A, Casey Genevieve P, Starkstein Sergio E, Clarnette Roger M, Almeida Osvaldo P, Davis Timothy M E
1School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia, Australia.
Diabetes Care. 2008 Nov;31(11):2103-7. doi: 10.2337/dc08-0562. Epub 2008 Jul 23.
The purpose of this study was to determine longitudinal predictors of cognitive decline in older individuals with diabetes who did not have dementia.
Cognitive assessments were performed in 205 subjects with diabetes (mean age 75.3 years) and repeated a median 1.6 years later. The sample was drawn from an existing cohort study, and data on diabetes, cardiovascular risk factors, and complications were collected 7.6 +/- 1.1 years before and at the time of the initial cognitive assessment. Cognitive status was defined using the Clinical Dementia Rating (CDR) scale, and cognitive decline was defined by change in CDR.
The sample included 164 subjects with normal cognition (CDR 0) and 41 with cognitive impairment without dementia (CDR 0.5). At follow-up, 33 (16.1%) had experienced cognitive decline (4 new cases of dementia and 29 cognitive impairment without dementia). Only educational attainment predicted cognitive decline from the data collected 7.6 years before cognitive assessment. Univariate predictors of cognitive decline at the time of the first cognitive assessment included age, education, urinary albumin-to-creatinine ratio (ACR), and treatment with either ACE inhibitors (ACEIs) or angiotensin receptor blockers (ARBs). With multiple logistic regression controlling for age and education, cognitive decline was predicted by natural logarithm ACR (odds ratio 1.37 [95% CI 1.05-1.78], P = 0.021), whereas treatment with either ACEIs or ARBs was protective (0.28 [0.12-0.65], P = 0.003).
In this sample of older patients with diabetes, microalbuminuria was a risk factor for cognitive decline, whereas drugs that inhibit the renin-angiotensin system were protective. These observations require confirmation because of their considerable potential clinical implications.
本研究旨在确定无痴呆的老年糖尿病患者认知功能下降的纵向预测因素。
对205名糖尿病患者(平均年龄75.3岁)进行认知评估,并在中位时间1.6年后重复评估。样本取自一项现有的队列研究,在首次认知评估前7.6±1.1年及评估时收集糖尿病、心血管危险因素和并发症的数据。使用临床痴呆评定量表(CDR)定义认知状态,认知功能下降由CDR的变化定义。
样本包括164名认知正常(CDR 0)的受试者和41名无痴呆的认知障碍受试者(CDR 0.5)。随访时,33名(16.1%)出现了认知功能下降(4例新发痴呆病例和29例无痴呆的认知障碍)。在认知评估前7.6年收集的数据中,只有受教育程度可预测认知功能下降。首次认知评估时认知功能下降的单因素预测因素包括年龄、教育程度、尿白蛋白肌酐比值(ACR)以及使用血管紧张素转换酶抑制剂(ACEI)或血管紧张素受体阻滞剂(ARB)治疗。在控制年龄和教育程度的多因素逻辑回归分析中,自然对数ACR可预测认知功能下降(比值比1.37[95%CI 1.05 - 1.78],P = 0.021),而使用ACEI或ARB治疗具有保护作用(0.28[0.12 - 0.65],P = 0.003)。
在这个老年糖尿病患者样本中,微量白蛋白尿是认知功能下降的危险因素,而抑制肾素 - 血管紧张素系统的药物具有保护作用。鉴于这些观察结果具有相当大的潜在临床意义,需要进一步证实。